An apolipoprotein A-I mimetic targets scavenger receptor a on tumor-associated macrophages: A prospective anticancer treatment?

OncoImmunology

Volumn 2, Issue 6, 2013, Pages

  Neyen, Claudine ^a   Mukhopadhyay, Subhankar ^a   Gordon, Siamon ^a   Hagemann, Thorsten ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Apo A I mimetic peptide; Co culture; Ligand; Scavenger receptor; Tumor associated macrophage

Indexed keywords

4F PEPTIDE; ANTINEOPLASTIC AGENT; APOLIPOPROTEIN A1; PROTEIN M2; PROTEOGLYCAN; SCAVENGER RECEPTOR A; STABILIN 2; TUMOR MARKER; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CANCER CELL CULTURE; DOWN REGULATION; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EXTRACELLULAR MATRIX; GENE INACTIVATION; HUMAN; LIPID PEROXIDATION; MOLECULAR INTERACTION; NONHUMAN; OVARY CANCER; OXIDATIVE STRESS; PANCREAS CANCER; PHENOTYPIC VARIATION; PROTEIN CARBONYLATION; PROTEIN EXPRESSION; PROTEIN LIPID INTERACTION; SIGNAL TRANSDUCTION; STOMACH CANCER; TUMOR ASSOCIATED LEUKOCYTE; TUMOR INVASION; TUMOR MICROENVIRONMENT; TUMOR PROMOTION;

EID: 84886945137     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.24461     Document Type: Article

References (10)

1. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004; 4:71-8; PMID:14708027; http://dx.doi. org/10.1038/nrc1256
2. Hagemann T, Wilson J, Burke F, Kulbe H, Li NF, Plüddemann A, et al. Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype. J Immunol 2006; 176:5023-32; PMID:16585599
3. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002; 23:549-55; PMID:12401408; http://dx.doi.org/10.1016/S1471-4906(02)02302-5
4. Neyen C, Plüddemann A, Mukhopadhyay S, Maniati E, Bossard M, Gordon S, et al. Macrophage scavenger receptor a promotes tumor progression in murine models of ovarian and pancreatic cancer. J Immunol 2013; 190:3798-805; PMID:23447685; http://dx.doi. org/10.4049/jimmunol.1203194
5. Hirose Y, Saijou E, Sugano Y, Takeshita F, Nishimura S, Nonaka H, et al. Inhibition of Stabilin-2 elevates circulating hyaluronic acid levels and prevents tumor metastasis. Proc Natl Acad Sci U S A 2012; 109:4263-8; PMID:22371575
6. Su F, Kozak KR, Imaizumi S, Gao F, Amneus MW, Grijalva V, et al. Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer. Proc Natl Acad Sci U S A 2010; 107:19997-20002; PMID:21041624; http://dx.doi.org/10.1073/pnas.1009010107
7. Su F, Grijalva V, Navab K, Ganapathy E, Meriwether D, Imaizumi S, et al. HDL mimetics inhibit tumor development in both induced and spontaneous mouse models of colon cancer. Mol Cancer Ther 2012; 11:1311-9; PMID:22416044; http://dx.doi. org/10.1158/1535-7163.MCT-11-0905
8. Ganapathy E, Su F, Meriwether D, Devarajan A, Grijalva V, Gao F, et al. D-4F, an apoA-I mimetic peptide, inhibits proliferation and tumorigenicity of epithelial ovarian cancer cells by upregulating the antioxidant enzyme MnSOD. Int J Cancer 2012; 130:1071-81; PMID:21425255; http://dx.doi. org/10.1002/ijc.26079
9. Watson CE, Weissbach N, Kjems L, Ayalasomayajula S, Zhang Y, Chang I, et al. Treatment of patients with cardiovascular disease with L-4F, an apo-A1 mimetic, did not improve select biomarkers of HDL function. J Lipid Res 2011; 52:361-73; PMID:21068008; http://dx.doi.org/10.1194/jlr. M011098
10. Bloedon LT, Dunbar R, Duffy D, Pinell-Salles P, Norris R, DeGroot BJ, et al. Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients. J Lipid Res 2008; 49:1344-52; PMID:18323573; http://dx.doi. org/10.1194/jlr. P800003-JLR200